Posted by Michael Wonder on 09 Feb 2022
FDA awards QIDP designation for prevention of chlamydia to Evofem Biosciences
9 February 2022 - Adds five years of market exclusivity on approval.
Evofem Biosciences announced today that the U.S. FDA has awarded qualified infectious disease product designation to EVO100 (the investigational name for Phexxi (lactic acid, citric acid and potassium bitartrate)) for the prevention of urogenital chlamydia infection in women, a potential new indication in late stage clinical development.
